Superior Glycaemic Control Effects with Dulaglutide (Dula), a Once-Weekly Glucagon-Like Peptide Receptor-Antagonist (GLP-1RA), to Liraglutide (Lira) in Diabetic Hemodialysis Patients Assessed by Continuous Glucose Monitoring (CGM)
- Resource Type
- Journal
- Source
DIABETES ; JUL 1 2018, 67 2p. Supplement: 1- Subject
- Language
- English
- ISSN
- 1939327X